- Home
- SPT vs NVCR Comparison
SPT vs NVCR Comparison
Compare SPT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- NVCR
- Stock Information
- Founded
- SPT 2010
- NVCR 2000
- Country
- SPT United States
- NVCR Switzerland
- Employees
- SPT N/A
- NVCR N/A
- Industry
- SPT Computer Software: Prepackaged Software
- NVCR Medical/Dental Instruments
- Sector
- SPT Technology
- NVCR Health Care
- Exchange
- SPT Nasdaq
- NVCR Nasdaq
- Market Cap
- SPT 1.1B
- NVCR 1.9B
- IPO Year
- SPT 2019
- NVCR 2015
- Fundamental
- Price
- SPT $19.19
- NVCR $17.60
- Analyst Decision
- SPT Buy
- NVCR Buy
- Analyst Count
- SPT 13
- NVCR 7
- Target Price
- SPT $31.69
- NVCR $32.43
- AVG Volume (30 Days)
- SPT 589.0K
- NVCR 1.3M
- Earning Date
- SPT 08-06-2025
- NVCR 07-24-2025
- Dividend Yield
- SPT N/A
- NVCR N/A
- EPS Growth
- SPT N/A
- NVCR N/A
- EPS
- SPT N/A
- NVCR N/A
- Revenue
- SPT $418,413,000.00
- NVCR $621,711,000.00
- Revenue This Year
- SPT $12.32
- NVCR $5.56
- Revenue Next Year
- SPT $11.90
- NVCR $9.19
- P/E Ratio
- SPT N/A
- NVCR N/A
- Revenue Growth
- SPT 17.79
- NVCR 18.27
- 52 Week Low
- SPT $18.52
- NVCR $14.17
- 52 Week High
- SPT $39.75
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- SPT 34.79
- NVCR 49.74
- Support Level
- SPT $19.88
- NVCR $16.81
- Resistance Level
- SPT $21.53
- NVCR $18.59
- Average True Range (ATR)
- SPT 0.71
- NVCR 0.74
- MACD
- SPT -0.06
- NVCR 0.08
- Stochastic Oscillator
- SPT 3.17
- NVCR 56.18
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.